Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2024-01-31 Earnings Release
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
2023年度业绩预告
Earnings Release Classification · 95% confidence The document is titled as a 2023 annual performance forecast (业绩预告) for Anhui Anke Biotechnology Engineering (Group) Co., Ltd. It provides estimated net profit figures for the full year 2023 and compares them to the prior year. It explicitly states that the financial data has not been audited by an accounting firm and that the detailed audited data will be disclosed in the 2023 annual report. The document is short (943 characters) and serves as a preliminary earnings forecast rather than a full financial report. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. It is not a full Annual Report (10-K) or Interim Report (IR) because it lacks detailed financial statements and is a forecast rather than actual results. Therefore, the correct classification is Earnings Release (ER). FY 2023
2024-01-31 Chinese
关于公司通过高新技术企业认定的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from Anhui Anke Biotechnology Engineering (Group) Co., Ltd. regarding the company's successful recognition as a high-tech enterprise by relevant provincial authorities. It includes details about the certificate number, issuance date, validity period, and tax benefits. The document is brief (586 characters) and does not contain financial statements, management discussion, or detailed report content. It is an official announcement about a certification or recognition, not a financial report or regulatory filing related to financial results or governance changes. It does not fit into categories like Annual Report, Interim Report, or Management Reports. It is also not a report publication announcement since it does not mention any report release. The best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2024-01-15 Chinese
关于AK1012吸入用溶液获得药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Anhui Anke Biotechnology (Group) Co., Ltd. regarding the approval of a clinical trial for a drug (AK1012 inhalation solution) by the National Medical Products Administration. It details the approval notice, drug development status, and risk warnings. The document is short (969 characters) and serves as an official announcement of regulatory approval rather than a financial report or detailed clinical data. It does not contain financial statements, management discussion, or other report content. It is a regulatory announcement about a clinical trial approval, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2023-12-18 Chinese
独立董事对相关事项之事前认可意见
Regulatory Filings Classification · 95% confidence The document is a statement of prior approval opinion by independent directors regarding a related party transaction involving the company's acquisition of part of a controlling subsidiary's equity. It references regulatory rules and internal company bylaws, and is a formal opinion rather than a full report or announcement of voting results. The document is short (404 characters) and does not contain financial statements or detailed financial data. It is not an annual report, audit report, or earnings release. It is not a voting result announcement or a proxy solicitation. It is a regulatory compliance-related document expressing independent directors' approval. Therefore, it fits best under Regulatory Filings (RNS) as a compliance disclosure that does not fit other categories.
2023-12-12 Chinese
关于高级管理人员辞职的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a senior management personnel (the CFO) and the appointment of a new CFO. It includes details about the resignation, shareholding, and compliance with relevant regulations. There is no financial data, report, or presentation content. This fits the category of Board/Management Information (MANG), which covers announcements of changes in senior management.
2023-12-12 Chinese
关于受让控股子公司部分股权暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company acquiring additional equity in a controlling subsidiary and details about the related party transaction. It includes information about the transaction, related parties, pricing policy, financial data of the subsidiary, and independent directors' opinions. The document is a formal announcement of a corporate transaction involving related parties and equity changes in a subsidiary. It does not contain full financial statements or comprehensive financial performance data, nor is it a report like an annual or interim report. It is not a call transcript, earnings release, or management report. The document is a regulatory announcement about a capital transaction and related party dealings. Therefore, it fits best under Capital/Financing Update (CAP). The document length is under 5,000 characters but contains substantive transaction details, so it is not merely a report publication announcement or a regulatory filing fallback. Confidence is high due to clear transaction and related party details.
2023-12-12 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.